HCPCS Level II J9299: Injection, nivolumab, 1 mg
HCPCS Level II code J9299 describes a billed unit for an injection of nivolumab, 1 mg, intended for systemic immunotherapy treatment; the service type is intravenous infusion/injection of an oncology biologic and the typical site of service is an outpatient infusion center or hospital outpatient department where oncology infusions are administered.
For related coverage guidance, see recent payer policy updates: Epithelial Cell Cytology in Breast Cancer Risk Assessment, Chimeric Antigen Receptor (CAR) T-Cell Therapy, Antibody-Drug Conjugates.
Customize your policy alerts
Sign up for hcpcs J9299 policy alerts
Get alerted when payer policies referencing J9299 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
National commercial pricing centers on a BUCA average commercial rate of $149.70 for J9299, while individual commercial payers cluster at substantially lower medians. Blue Cross Blue Shield and Cigna both show medians near $32–$33, and UnitedHealth Group’s median is $34.90. Aetna displays extreme dispersion driven by outliers, with a mean far above others at $843.90 and a wide spread between its P25 ($16.50) and P75 ($34.00).
Comparing interquartile dispersion (P75 minus P25), Aetna is the widest with a range of $17.50, indicating greater variability in typical commercial payments. UnitedHealth Group and Blue Cross Blue Shield are tighter, with ranges of $4.70 and $1.20 respectively, while Cigna’s IQR is $5.80 and BUCA’s IQR is $6.70, placing them in a mid-range of dispersion.